Guardant Health
GH
$16.67
Share price
1.71%
Change (1 day)
-32.10%
Change (1 year)
Categories
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.
Revenue for Guardant Health (GH)
Revenue in 2023 (TTM): $0.56 B
According to Guardant Health 's latest financial reports the company's current revenue (TTM) is $0.56 B. In 2022 the company made a revenue of $0.44 B an increase over the years 2021 revenue that were of $0.37 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Guardant Health from 2018 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $0.56 B | 25.45% |
| 2022 | $0.44 B | 20.31% |
| 2021 | $0.37 B | 30.32% |
| 2020 | $0.28 B | 33.75% |
| 2019 | $0.21 B | 136.52% |
| 2018 | $90.63 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Neogen NEOG | $0.92 B | 64.77% | 🇺🇸 USA |
 Natera NTRA | $1.08 B | 91.96% | 🇺🇸 USA |